Sydicom tailors your CV, cover letter and answers to this role to help you secure the interview. Free to start.
A remote role at BillionToOne.
How Sydicom helps: we read this listing’s requirements and tune your CV and cover letter to the keywords its ATS (Greenhouse) is scanning for, wherever you are, then help you apply.
“This is my first invitation to an interview since I have been applying since April.”
Original listing text, shown exactly as published by the company.
A Rare Opportunity to Shape the Future of Genomics
Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.
Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.
Sign in to see the rest of this description and apply. Browsing and matching are free, and we tailor your CV, cover letter and answers to this job so you get past the screening.
Sign in to continueFree to join. No card needed.
Sydicom has AI tools for your job search. See all tools
Moneybox
Farther
Carrot
knownwell
Centivo
BillionToOne
YC S17Other
9 open roles on Sydicom
BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.
Source: Y Combinator
